Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury

Journal of Clinical Investigation

Volumn 126, Issue 9, 2016, Pages 3336-3350

  Pedigo, Christopher E ^a   Ducasa, Gloria Michelle ^a   Leclercq, Farah ^a   Sloan, Alexis ^a   Mitrofanova, Alla ^a   Hashmi, Tahreem ^a   Molina David, Judith ^a   Ge, Mengyuan ^a   Lassenius, Mariann I ^b,c   Forsblom, Carol ^b,c   Lehto, Markku ^b,c   Groop, Per Henrik ^b,c,d   Kretzler, Matthias ^e   Eddy, Sean ^e   Martini, Sebastian ^e   Reich, Heather ^f   Wahl, Patricia ^a   Ghiggeri, Gian Marco ^g   Faul, Christian ^a   Burke, George W ^a   Kretz, Oliver ^h,i   Huber, Tobias B ^h,j   Mendez, Armando J ^a   Merscher, Sandra ^a   Fornoni, Alessia ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g G GASLINI INSTITUTE   (Italy)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CALCINEURIN; CASPASE 3; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; CYCLODEXTRIN; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METHYL BETA CYCLODEXTRIN; TRANSCRIPTION FACTOR NFAT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ABCA1 PROTEIN, HUMAN; ABCA1 PROTEIN, MOUSE; NFATC1 PROTEIN, HUMAN; NFATC1 PROTEIN, MOUSE; STEROL O-ACYLTRANSFERASE 1; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE SILENCING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY HYPERTROPHY; LIPID HOMEOSTASIS; MOUSE; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ADOLESCENT; ANIMAL; BAGG ALBINO MOUSE; BIOPSY; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CHILD; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION RATE; INFLAMMATION; KIDNEY; MALE; METABOLISM; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ALBUMINURIA; ANIMALS; APOPTOSIS; ATP BINDING CASSETTE TRANSPORTER 1; BIOPSY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CYCLODEXTRINS; DIABETIC NEPHROPATHIES; FEMALE; GENE EXPRESSION REGULATION; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INFLAMMATION; KIDNEY; MALE; MICE; MICE, INBRED BALB C; NEPHROTIC SYNDROME; NFATC TRANSCRIPTION FACTORS; PODOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STEROL O-ACYLTRANSFERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84987776738     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85939     Document Type: Article

References (68)

1. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355(7):704-712
2. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991;87(3):949-954
3. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6(6):410-417
4. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165-178
5. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152(4):673-684
6. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42(1):53-61
7. Moriwaki Y, et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metab Clin Exp. 2003;52(5):605-608
8. Pavkov ME, et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 2016;89(1):226-234
9. Gohda T, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516-524
10. Niewczas MA, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23(3):507-515
11. Forsblom C, et al. Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care. 2014;37(8):2334-2342
12. Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 2015;87(4):812-819
13. Peyser A, et al. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol. 2010;11:2
14. Joy MS, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55(1):50-60
15. Rohatgi A, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-2393
16. Fornoni A, Merscher S, Kopp JB. Lipid biology of the podocyte-new perspectives offer new opportunities. Nat Rev Nephrol. 2014;10(7):379-388
17. Merscher-Gomez S, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 2013;62(11):3817-3827
18. Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561-572
19. Cattran DC, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int. 2007;72(12):1429-1447
20. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991;352(6338):803-807
21. Gómez-Sintes R, Lucas JJ. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest. 2010;120(7):2432-2445
22. Faul C, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931-938
23. Maitra U, Parks JS, Li L. An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol Cell Biol. 2009;29(22):5989-5997
24. Martini S, et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol. 2014;25(11):2559-2572
25. Hodgin JB, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes. 2013;62(1):299-308
26. Ju W, et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 2013;23(11):1862-1873
27. Gerbod-Giannone MC, et al. TNFα induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc Natl Acad Sci U S A. 2006;103(9):3112-3117
28. Zhang Y, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 2010;121(11):1347-1355
29. Tejada T, et al. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int. 2008;73(12):1385-1393
30. Devries-Seimon T, et al. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol. 2005;171(1):61-73
31. Kellner-Weibel G, et al. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol. 1998;18(3):423-431
32. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature. 2005;438(7068):612-621
33. Wang Y, et al. Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol. 2010;21(10):1657-1666
34. Harrison BC, et al. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol. 2004;24(24):10636-10649
35. Nijenhuis T, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719-1732
36. Wilkins BJ, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94(1):110-118
37. Winslow MM, et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell. 2006;10(6):771-782
38. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24(8):1445-1452
39. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci. 1991;104(2):230-234
40. Vernooy JH, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166(9):1218-1224
41. Pierine DT, et al. Lycopene supplementation reduces TNF-α via RAGE in the kidney of obese rats. Nutr Diabetes. 2014;4:e142
42. Trachtman H, et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol. 2015;16:111
43. Yoo TH, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26(1):133-147
44. Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res. 2013;162(5):287-296
45. Wei C, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-960
46. Delville M, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra136
47. Savin VJ, et al. Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res. 2015;2015:714964
48. Saurus P, et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis. 2015;6:e1752
49. Lassenius MI, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011;34(8):1809-1815
50. Stanley AC, et al. The Rho GTPase Rac1 is required for recycling endosome-mediated secretion of TNF in macrophages. Immunol Cell Biol. 2014;92(3):275-286
51. Yabal M, et al. XIAP restricts TNF-and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014;7(6):1796-1808
52. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104-116
53. Field FJ, Watt K, Mathur SN. TNF-α decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res. 2010;51(6):1407-1415
54. Chang YC, Lee TS, Chiang AN. Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages. J Lipid Res. 2012;53(9):1840-1850
55. Pramanik R, et al. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem. 2003;278(7):4831-4839
56. Fazio S, et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001;107(2):163-171
57. Zimmer S, et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med. 2016;8(333):333ra50
58. Isnard Bagnis C, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13(12):2962-2968
59. Fornoni A, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46
60. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care. 2011;34(1):177-180
61. Sampson MG, et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J Am Soc Nephrol. 2016;27(3):814-823
62. Saleem MA, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13(3):630-638
63. Fitzgerald ML, Mendez AJ, Moore KJ, Andersson LP, Panjeton HA, Freeman MW. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J Biol Chem. 2001;276(18):15137-15145
64. Mendez AJ. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res. 1997;38(9):1807-1821
65. Khera AV, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135
66. Timmins JM, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115(5):1333-1342
67. Grabner A, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020-1032
68. Kato H, et al. Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011;286(29):26003-26015